Gleiss Lutz advises KKR on the acquisition of Bayer’s Diabetes Care business
The US private equity investor Kohlberg Kravis Roberts & Co. (KKR) will be taking over Bayer AG’s Diabetes Care business for EUR 1.022 billion via its portfolio company, Panasonic Healthcare Co., Ltd. KKR and Bayer AG announced the execution of a definitive agreement for the acquisition today. Closing of the transaction is subject to the customary conditions, including clearance by the relevant antitrust authorities, and is expected to take place in the first quarter of 2016.